Please assess the completion status of the following clinical trial:

Trial Title: 1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed adenocarcinoma of the breast.~* Measurable or evaluable locally advanced or metastatic disease.~* Age ≥18 years.~* Disease progression during or after treatment with a bevacizumab-containing regimen in the adjuvant or first-line metastatic setting.~* Patients must have discontinued chemotherapy at least 3 weeks prior to randomization.~* No more than one prior chemotherapy regimen for locally advanced or metastatic disease.~* Prior hormonal therapy allowed provided it has been discontinued prior to randomization.~* Prior radiation therapy is allowed but must be completed at least 3 weeks prior to randomization. Previously radiated area(s) must not be the only site of disease.~* ECOG Performance Status of 0 or 1.~* Adequate bone marrow, liver, and renal function~* Women of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to randomization, and must agree to use adequate contraception prior to study entry, for the duration of study participation and 28 days after the last study drug dosing.~* Patients must be able and willing to sign a written informed consent.~* Patients must be able to swallow and retain oral medication.~Exclusion Criteria:~* Patients with breast cancer over-expressing human epidermal growth factor receptor 2 (HER-2) (gene amplification by FISH or 3+ over-expression by immunohistochemistry). Patients with unknown HER-2 status are not eligible.~* Patients with active brain metastases.~* Major surgery, open biopsy, or significant traumatic injury within 4 weeks of randomization.~* Prior use of gemcitabine/capecitabine or sorafenib.~* Evidence or history of bleeding diathesis or coagulopathy.~* Serious, non-healing wound, ulcer, or bone fracture.~* Substance abuse, or medical, psychological, or social condition that may interfere with the patient's participation in the study or evaluation of the study results.~* Use of cytochrome P450 enzyme-inducing anti-epileptic drugs is not allowed.~* Clinically significant cardiac disease~* Uncontrolled hypertension~* Thrombolic, embolic, venous, or arterial events such as a cerebrovascular accident including transient ischemic attacks within the past 6 months.~* Pulmonary hemorrhage/bleeding event \> NCI-CTCAE Grade 2 within 4 weeks of randomization.~* Any other hemorrhage/bleeding event ≥ NCI-CTCAE Grade 3 within 4 weeks of randomization.~* Active clinically serious infection \> NCI-CTCAE Grade 2.~* Known HIV infection or chronic hepatitis B or C (the safety and effectiveness of sorafenib in this patient population have not been studied).~* Previous or concurrent cancer that is distinct in primary site or histology from breast cancer EXCEPT cervical cancer in-situ, treated basal cell carcinoma, superficial bladder tumors \[Ta and Tis\] or any cancer curatively treated \> 5 years prior to randomization.~* Known or suspected allergy to sorafenib or gemcitabine/capecitabine.~* Prior or concurrent use of St. John's Wort or rifampin (rifampicin) within 3 weeks of randomization.~* Concurrent anti-cancer therapy other than gemcitabine/capecitabine and sorafenib/placebo.~* Prior treatment with any agent that targets VEGF or VEGFR (licensed or investigational), except bevacizumab.~* Women who are pregnant or breast-feeding.~* Use of any investigational drug within 30 days or 5 half-lives, whichever is longer, preceding randomization.~* Inability to comply with protocol and/or not willing or not available for follow-up assessments.~* Any condition which in the investigator's opinion makes the patient unsuitable for the study participation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A (Sorafenib + Gemcitabine or Capecitabine) (Type: ACTIVE_COMPARATOR): Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)
- B (Placebo + Gemcitabine or Capecitabine) (Type: PLACEBO_COMPARATOR): Placebo will be administered ( 2 tablets ) orally twice daily (approximately every 12 hours); Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle; Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine)

Based on this trial design, predict the completion outcome and termination type (if applicable).